|
MID1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
1.44440000005019E-06 |
| Normal-vs-Stage3 |
8.84292639113937E-13 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
4.723800E-02 |
| Stage1-vs-Stage3 |
9.995000E-01 |
| Stage1-vs-Stage4 |
6.213400E-04 |
| Stage2-vs-Stage3 |
9.847600E-02 |
| Stage2-vs-Stage4 |
4.961200E-04 |
| Stage3-vs-Stage4 |
1.072000E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.44089209850063E-16 |
| Normal-vs-AfricanAmerican |
4.6062999969898E-08 |
| Normal-vs-Asian |
1.62680979798324E-12 |
| Caucasian-vs-AfricanAmerican |
7.743200E-01 |
| Caucasian-vs-Asian |
1.015210E-01 |
| AfricanAmerican-vs-Asian |
1.563370E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.88498130835069E-15 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
7.742600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
2.68639555045525E-11 |
| Normal-vs-Age(81-100Yrs) |
1.048070E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.063000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.914000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.978830E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.294400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.843030E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.971800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.702440E-01 |
| Classical-VS-Follicular |
2.33959999995648E-06 |
| Classical-VS-Other |
1.507640E-02 |
| Classical-VS-Normal |
1.62470037423645E-12 |
| Tall-VS-Follicular |
9.50880000000209E-05 |
| Tall-VS-Other |
4.020400E-01 |
| Tall-VS-Normal |
1.98419058961008E-12 |
| Follicular-VS-Other |
1.62491999999848E-05 |
| Follicular-VS-Normal |
9.81769999963689E-07 |
| Other-VS-Normal |
1.11890052778563E-10 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.36952687973735E-13 |
| Normal-vs-N1 |
1.11022302462516E-16 |
| N0-vs-N1 |
6.657100E-03 |
|
|
